ライフサイエンスコーパス: oesophageal

1 rectal, breast, prostate, lung, stomach, and oesophageal.

2 1.59, p<0.0001), gallbladder (1.59, p=0.04), oesophageal adenocarcinoma (1.51, p<0.0001), and renal (

3 studies on chromosome 17 (C17) in Barrett's oesophageal adenocarcinoma (BOA) tumours strongly sugges

4 Oesophageal adenocarcinoma (EAC) incidence is rapidly in

5 Compared with never users, HR for oesophageal adenocarcinoma (n=37 cases) in current NSAID

6 Oesophageal adenocarcinoma (OAC) is increasing in incide

7 by whole genome sequencing (WGS) studies in oesophageal adenocarcinoma (OAC).

8 Lactobacillus fermentum was enriched in oesophageal adenocarcinoma (p=0.028), and lactic acid ba

9 (rs9823696) was associated specifically with oesophageal adenocarcinoma (p=1.6 x 10(-8)) and was inde

10 increase in BMI was strongly associated with oesophageal adenocarcinoma (RR 1.52, p<0.0001) and with

11 dysplastic Barrett's oesophagus [n=23], and oesophageal adenocarcinoma [n=19]), relevant negative co

12 Both oesophageal adenocarcinoma and Barrett's metaplasia are

13 sess the role of NSAID in the development of oesophageal adenocarcinoma and precursor lesions in peop

14 known risk loci for Barrett's oesophagus and oesophageal adenocarcinoma and revealed new insights int

15 urthermore, the specific association between oesophageal adenocarcinoma and the locus near HTR3C and

16 ociation studies of Barrett's oesophagus and oesophageal adenocarcinoma available in PubMed up to Feb

17 Patients with surgically resectable oesophageal adenocarcinoma classified as stage cT1N1, cT

18 Oesophageal adenocarcinoma conveys a poor prognosis and

19 , the associations were strengthened: HR for oesophageal adenocarcinoma for current users at baseline

20 herapy can rapidly and profoundly affect the oesophageal adenocarcinoma genome.

21 known as Barrett's oesophagus can evolve to oesophageal adenocarcinoma in decades-long processes of

22 Oesophageal adenocarcinoma is increasing rapidly in the

23 asia; however their effect on development of oesophageal adenocarcinoma is less clear.

24 The strongest risk factor for oesophageal adenocarcinoma is reflux disease, and the ri

25 Oesophageal adenocarcinoma represents one of the fastest

26 and neck squamous-cell carcinoma, or gastro-oesophageal adenocarcinoma that had relapsed or was refr

27 There was decreased microbial diversity in oesophageal adenocarcinoma tissue compared with tissue f

28 5-year cumulative incidence of oesophageal adenocarcinoma was 14.3% (95% CI 9.3-21.6) f

29 Barrett's metaplasia (a precursor lesion for oesophageal adenocarcinoma) has an increasing incidence.

30 d it is a risk factor for the development of oesophageal adenocarcinoma, a cancer with rapidly increa

31 cy, and recency of NSAID use and the risk of oesophageal adenocarcinoma, aneuploidy, and tetraploidy

32 rrett's oesophagus and 4112 individuals with oesophageal adenocarcinoma, in addition to 17 159 repres

33 ing the genetics of Barrett's oesophagus and oesophageal adenocarcinoma, we aimed to identify novel g

34 arrett's oesophagus is the main precursor to oesophageal adenocarcinoma, which has a poor prognosis.

35 the development of Barrett's oesophagus and oesophageal adenocarcinoma, which might encourage develo

36 t predisposes patients to the development of oesophageal adenocarcinoma, which, once invasive, carrie

37 sociated with either Barrett's oesophagus or oesophageal adenocarcinoma, within or near the genes CFT

38 squamous-cell carcinoma, and 55 with gastro-oesophageal adenocarcinoma.

39 arrett's oesophagus, the precursor lesion to oesophageal adenocarcinoma.

40 plastic disorder that confers a high risk of oesophageal adenocarcinoma.

41 patients with MET-positive gastric or gastro-oesophageal adenocarcinoma.

42 croenvironment in seven (47%) of 15 cases of oesophageal adenocarcinoma.

43 gastric, oesophagogastric junction, or lower oesophageal adenocarcinoma.

44 gastric, oesophagogastric junction, or lower oesophageal adenocarcinoma.

45 the development of Barrett's oesophagus and oesophageal adenocarcinoma.

46 oesophagus is the premalignant precursor of oesophageal adenocarcinoma.

47 the transition from Barrett's oesophagus to oesophageal adenocarcinoma.

48 ative growth whose eradication could prevent oesophageal adenocarcinoma.

49 our (9%, 2-20) of 47 individuals with gastro-oesophageal adenocarcinoma; all were partial responses.

50 whole-exome and deep sequencing of 30 paired oesophageal adenocarcinomas sampled before and after neo

51 vide new insight into the preventive role of oesophageal ALDH2 against acetaldehyde-derived DNA damag

52 Quantifications of gastro-oesophageal anatomy in cadavers have led some to identif

53 with the occurrence and the status of colon, oesophageal and breast cancers.

54 roximated to Odds Ratio for rare events) for oesophageal and gastric cancer development in bisphospho

55 sis and methylation, and may protect against oesophageal and gastric cancers.

56 nd over compared with those under 40 years); oesophageal and gastric/duodenal malignancy (48 and 32 r

57 that project to the STG through the superior oesophageal and stomatogastric nerves, presumably from c

58 the STG and at the junction of the superior oesophageal and stomatogastric nerves.

59 owever, including high-grade serous ovarian, oesophageal, and small-cell lung cancer, are driven by s

60 lish its role for neonatal disorders such as oesophageal atresia and biliary atresia through clinical

61 ase with severe bilateral microphthalmia and oesophageal atresia has a de novo missense mutation, R74

62 resection, congenital diaphragmatic hernia, oesophageal atresia, and ruptured omphalocele or gastros

63 ncreased proliferation and aneuploidy in the oesophageal basal epithelium.

64 EoE-A children had increased iNKT levels in oesophageal biopsies compared with EoE-C children.

65 P < 0.001) and distal (2.9-fold, P < 0.001) oesophageal biopsies from EoE patients.

66 now show that cytoglobin gene expression in oesophageal biopsies from tylotic patients is dramatical

67 nology) was performed on proximal and distal oesophageal biopsies of 30 paediatric EoE patients and 4

68 elevated levels of IL-23 mRNA were found in oesophageal biopsies of patients with reflux oesophagiti

69 INKTs from peripheral blood (PB) and oesophageal biopsies were studied.

70 to the Rome II FGID categories of functional oesophageal, bowel and anorectal disorders, and to the s

71 circulating tumour cells (CTCs) in advanced oesophageal cancer (EC) patients undergoing concurrent c

72 ciated with the early onset of squamous cell oesophageal cancer (SCOC) in three families.

73 lotype analyses have mapped the tylosis with oesophageal cancer (TOC) locus to a 42.5 kb region on ch

74 ned entirely within the 42.5 kb tylosis with oesophageal cancer (TOC) minimal region.

75 on mutations in iRHOM2 underlie Tylosis with oesophageal cancer (TOC), characterized by palmoplantar

76 cancer-susceptibility syndrome tylosis with oesophageal cancer (TOC), suggesting a role for this pro

77 rative effects in colonic mucosa and in some oesophageal cancer cell lines.

78 the recently published chemoradiotherapy for oesophageal cancer followed by surgery study trial showe

79 urgical resection for stage III or IV distal oesophageal cancer in 1987-2010 with follow-up until 201

80 EMS placement as sole therapy for inoperable oesophageal cancer in a resource-limited setting.

81 ce for an increase in the risk of gastric or oesophageal cancer in bisphosphonate users and one findi

82 an appropriate technology for palliation of oesophageal cancer in resource-limited settings.

83 ost all patients who underwent resection for oesophageal cancer in Sweden in 1987-2010.

84 e of gefitinib as a second-line treatment in oesophageal cancer in unselected patients does not impro

85 rt a small but significant increased risk of oesophageal cancer in women prescribed bisphosphonates a

86 Therapies for inoperable oesophageal cancer include chemoradiotherapy and placeme

87 Endoscopically diagnosed oesophageal cancer increased by 32 % per decade, but gas

88 Oesophageal cancer is a clinically challenging disease t

89 Oesophageal cancer is one of the 10 leading causes of ca

90 c role of lymphadenectomy during surgery for oesophageal cancer is questioned.

91 a small but significantly increased risk of oesophageal cancer linked to duration of bisphosphonate

92 of Life Questionnaire-Core 30 (QLQ-C30) and -Oesophageal Cancer Module (QLQ-OES24) questionnaires pre

93 eligible patients were adults with advanced oesophageal cancer or type I/II Siewert junctional tumou

94 carce for the effectiveness of therapies for oesophageal cancer progressing after chemotherapy, and n

95 the promoter is hypermethylated in sporadic oesophageal cancer samples: this may constitute the 'sec

96 rapy cannot be recommended for patients with oesophageal cancer suitable for definitive CRT.

97 Lymphadenectomy during oesophageal cancer surgery is a safe procedure in the sh

98 Eligible patients had biopsy-proven oesophageal cancer that was unsuitable for curative trea

99 ls in a collection of DNA samples taken from oesophageal cancer tissues.

100 prospectively gathered on all patients with oesophageal cancer treated with SEMS between Jan 1, 1999

101 ncluded patients with advanced or metastatic oesophageal cancer who were randomly assigned (1:1) thro

102 Thus, patients with distal oesophageal cancer with coeliac node metastasis seem to

103 The odds of being a case of oesophageal cancer, adjusted for smoking status, were si

104 S are placed in all patients with inoperable oesophageal cancer, as in our study, rather than those f

105 For lung and oesophageal cancer, benefit was confined to adenocarcino

106 er cardiovascular and circulatory disorders, oesophageal cancer, preterm birth complications, congeni

107 are the cause of the inherited cutaneous and oesophageal cancer-susceptibility syndrome tylosis with

108 dence for surgery in the treatment of gastro-oesophageal cancer.

109 with placebo in previously treated advanced oesophageal cancer.

110 the development of Barrett's metaplasia and oesophageal cancer.

111 SEMS effectively palliate inoperable oesophageal cancer.

112 n is the mainstay of treatment for localised oesophageal cancer.

113 d epigenetically or in regulatory regions in oesophageal cancer.

114 ry as standard treatment of locally advanced oesophageal cancer.

115 ompared with surgery alone for patients with oesophageal cancer.

116 tasis precludes long-term survival in distal oesophageal cancer.

117 lignant dysphagia in patients with incurable oesophageal cancer.

118 , ongoing controversies, and future needs in oesophageal cancer.

119 sociation was seen with risk or survival for oesophageal cancer.

120 nut are known risk factors for many oral and oesophageal cancers, and their use is highly prevalent i

121 Two HIV-related diagnoses, oesophageal candidiasis and Kaposi's sarcoma, rose from

122 Oesophageal carcinoma affects more than 450,000 people w

123 The overall 5-year survival of patients with oesophageal carcinoma ranges from 15% to 25%.

124 Oesophageal carcinoma with associated aberrant R/subclav

125 She was found to have a oesophageal carcinoma with incidentally co-existing aber

126 us-cell carcinoma is the predominant form of oesophageal carcinoma worldwide, but a shift in epidemio

127 When associated with oesophageal carcinoma, it can cause diagnostic confusion

128 ss, but also results in an increased risk of oesophageal carcinoma.

129 ive to surgery for the curative treatment of oesophageal carcinoma.

130 prevention, and advances in the treatment of oesophageal carcinoma.

131 rticularly the case in patients with lung or oesophageal carcinoma.

132 igated to improve outcomes for patients with oesophageal carcinoma.

133 0 years old with breast or gastric or gastro-oesophageal carcinomas refractory to standard therapy re

134 EMGdi was measured with a multipair oesophageal catheter passed per-nasally.

135 the question of whether the peptidergic post-oesophageal commissure (POC) neurons trigger a specific

136 e, and has not yet been used to repair large oesophageal defects in human beings.

137 al regulator known to be critical for normal oesophageal development in humans.

138 eartburn and chest pain were included in the oesophageal discomfort factor.

139 68% of the variance and these were termed: 'oesophageal discomfort', 'bowel dysfunction', 'abdominal

140 m nociceptors by their saturable response to oesophageal distension and by the lack of TRPV1.

141 Furthermore, the method of oesophageal distension has significant influence on the

142 te noxious mechanical stimuli (wide range of oesophageal distension with pressure up to 100 mmHg) and

143 tion of atropine (15 microg kg-1, I.V.), the oesophageal distensions were repeated.

144 Oesophageal distensions with either isovolumic (5-20 ml

145 erioperative haemodynamic optimization using oesophageal Doppler monitoring and should be considered

146 nt evidence exists to justify routine use of oesophageal Doppler monitoring to guide perioperative ha

147 clinicopathologic condition characterized by oesophageal dysfunction and eosinophil-predominant infla

148 cal history is vital for distinguishing true oesophageal dysphagia from oropharyngeal dysphagia or ot

149 Oesophageal dysphagia is a so-called red flag alarm symp

150 agnosis of EoE is reserved for patients with oesophageal eosinophilia and symptoms that do not respon

151 end a trial of PPI therapy for patients with oesophageal eosinophilia and symptoms, even when the dia

152 ying 'proton pump inhibitor (PPI) responsive oesophageal eosinophilia' in eosinophilic oesophagitis (

153 ied disease phenotype called 'PPI-responsive oesophageal eosinophilia'.

154 and the mechanisms underlying PPI-responsive oesophageal eosinophilia.

155 iNKT levels are higher at the site of active oesophageal eosinophilic inflammation.

156 matched stem cells of Barrett's, gastric and oesophageal epithelia that yield divergent tumour types

157 sion was localised to the basal layer of the oesophageal epithelium.

158 e miRNAs localised to the basal layer of the oesophageal epithelium.

159 on, we developed an in vitro model, based on oesophageal explants isolated from E11.5d mouse embryos,

160 Elevated oesophageal expression of LTC4 S mRNA is found in a subg

161 20 patients with a tracheo-oesophageal fistula lived a median of 142 days (IQR 73-3

162 l atresia, cardiovascular anomalies, trachea-oesophageal fistula, renal anomalies, limb defects (VACT

163 Foregut division-the separation of dorsal (oesophageal) from ventral (tracheal) foregut components-

164 this approach might not be representative of oesophageal function during the ingestion of normal food

165 as immunopositive somata in the CoGs and the oesophageal ganglion.

166 n proximal and distal dysmotility syndromes (oesophageal, gastric and colorectal), and induced mast c

167 ive than similar postoperative treatment for oesophageal, gastric, and rectal cancers, perhaps becaus

168 consistent reductions were seen in risks of oesophageal, gastric, biliary, and breast cancer.

169 graphy probe was used to record pressure and oesophageal geometry.

170 ode effector proteins are synthesized in the oesophageal glands and are secreted into plant tissues t

171 variants in three squamous-cell carcinomas (oesophageal, head and neck and lung) significantly promo

172 o treat the most debilitating aspect of EoE, oesophageal inflammation and remodelling.

173 Understanding the role of oesophageal inflammation will provide important insight

174 ibed the first such system to arise from the oesophageal International Cancer Genome Consortium proje

175 used propofol TCI sedation during endoscopic oesophageal interventions.

176 endoscopists than propofol during endoscopic oesophageal interventions?

177 optimum procedure for reconstruction of the oesophageal-intestinal tract is a highly debated topic.

178 adenocarcinomas of the oesophagus and gastro-oesophageal junction (Siewert types 1 and 2).

179 ars or older with advanced gastric or gastro-oesophageal junction adenocarcinoma and disease progress

180 24-87 years with advanced gastric or gastro-oesophageal junction adenocarcinoma and disease progress

181 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after fi

182 lly advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma, an Eastern Cooperat

183 with advanced MET-positive gastric or gastro-oesophageal junction adenocarcinoma.

184 anorectal junction) as well as in the gastro-oesophageal junction in the human gut.

185 ncer, including adenocarcinoma of the gastro-oesophageal junction).

186 , intestinal metaplasia occurs at the gastro-oesophageal junction, where stratified squamous epitheli

187 atic adenocarcinoma of the stomach or gastro-oesophageal junction.

188 atic adenocarcinoma of the stomach or gastro-oesophageal junction.

189 In transformed oesophageal keratinocytes, CD44(Low)-CD24(High) (CD44L)

190 ced ALDH2 production in both mouse and human oesophageal keratinocytes.

191 Oesophageal, LOS and gastric pressures were measured usi

192 Oesophageal, LOS and gastric pressures were measured usi

193 Together with TSLP and IL-23 mRNA levels, oesophageal LTC4 S mRNA may facilitate diagnosis of an E

194 on mutations in this transcription factor in oesophageal malformations.

195 denoscopy (with biopsy), barium swallow, and oesophageal manometry, no obstructive cause may be found

196 s a minimally invasive tool for sampling the oesophageal microbiota.

197 bacter pylori, both of which might alter the oesophageal microbiota.

198 g that apoptosis is not required for tracheo-oesophageal morphogenesis.

199 non-diabetics, which may be related to worse oesophageal motility and, thus, a more functional rather

200 high-resolution manometry (HRM) to diagnose oesophageal motility disorders is based on ten single wa

201 Diagnosis of oesophageal motility disorders was based on the Chicago

202 , 194, 203, 205 and 215 expression levels in oesophageal mucosa from individuals without pathological

203 of 10 TDFs from OAC with 12 NDF from normal oesophageal mucosa using Infinium HumanMethylation450 Be

204 ellular localisation of microRNAs within the oesophageal mucosa was determined using in-situ hybridis

205 d following transfection of a human squamous oesophageal mucosal cell line (Het-1A).

206 on has been proposed to underlie the loss of oesophageal neurons, particularly in genetically suscept

207 and also no apparent risk in men for either oesophageal or gastric cancer, odds ratio adjusted for s

208 ly, inactivation of NANOG in cell lines from oesophageal or head and neck squamous cell carcinomas (E

209 herefore, recruitment of patients with lower oesophageal or junctional tumours planned for an oesopha

210 re an effect on deaths was about 5 years for oesophageal, pancreatic, brain, and lung cancer, but was

211 ients undergoing general anaesthesia for non-oesophageal pathology were administered cisatracurium to

212 ressure (DeltaP(GA)) = <2 cmH(2)O, change in oesophageal pressure (DeltaP(ES)) = approximately -6 cmH

213 BF, thermodilution), cardiac output (Q), and oesophageal pressure (P(pl), index of pleural pressure).

214 ient across the upper airway (estimated with oesophageal pressure, Pes) during polysomnography in fou

215 oscopic dilatations, and for advanced cases, oesophageal reconstruction.

216 Gastro-oesophageal reflux (GER) and microaspiration have been p

217 Gastro-Oesophageal Reflux (GOR) is a key problem in Cystic Fibr

218 may have implications in treatment of gastro-oesophageal reflux and other upper gut disorders.

219 may have implications in treatment of gastro-oesophageal reflux and other upper gut disorders.

220 5 levels were significantly higher in gastro-oesophageal reflux compared with controls.

221 Scales for aiding physicians diagnose gastro-oesophageal reflux disease (GERD) have not been evaluate

222 Information about gastro-oesophageal reflux disease (GERD) in patients with Diabe

223 Treatment-refractory gastro-oesophageal reflux disease (GERD) remains a significant

224 phageal symptoms and the aetiology of gastro-oesophageal reflux disease (GORD) remains unclear.

225 k: 7027), sinusitis 42.3% (5870), and gastro-oesophageal reflux disease 39.3% (5650).

226 The incidence of gastro-oesophageal reflux disease and Barrett's oesophagus is i

227 Approximately 20% have gastro-oesophageal reflux disease and this can be effectively t

228 Gastro-oesophageal reflux disease is a potential risk factor fo

229 cal disorders (asthma, sinusitis, and gastro-oesophageal reflux disease), mental health disorders (de

230 seems to be a complication of chronic gastro-oesophageal reflux disease, although asymptomatic indivi

231 failure, sleep-disordered breathing, gastro-oesophageal reflux disease, and anxiety or depression.

232 s) is a pathological manifestation of gastro-oesophageal reflux disease, and is a major risk factor f

233 ronic cough is usually due to asthma, gastro-oesophageal reflux disease, and upper airway conditions,

234 lude asthma, eosinophilic bronchitis, gastro-oesophageal reflux disease, postnasal drip syndrome or r

235 evelopment of non-drug treatments for gastro-oesophageal reflux disease, safety of long-term drug tre

236 be similar to those of patients with gastro-oesophageal reflux disease.

237 ople who experience daily symptoms of gastro-oesophageal reflux have lower blood pressure than people

238 gnosis and treatment of abnormal acid gastro-oesophageal reflux in each trial.

239 Abnormal acid gastro-oesophageal reflux is common in patients with idiopathic

240 ts) for patients with IPF, in the absence of oesophageal reflux or symptoms.

241 patients with IPF, and abnormal acid gastro-oesophageal reflux seems to contribute to disease progre

242 from individuals without pathological gastro-oesophageal reflux to individuals with ulcerative oesoph

243 etween blood pressure and symptoms of gastro-oesophageal reflux was examined.

244 hypertension, digital ulceration, and gastro-oesophageal reflux, are now treatable.

245 vago-vagal reflex that can result in gastro-oesophageal reflux, that is, gastric distension-evoked l

246 vago-vagal reflex that can result in gastro-oesophageal reflux, that is, gastric distension-evoked l

247 ation in response to injury caused by gastro-oesophageal reflux.

248 RNA gene amplicon sequencing was done on 210 oesophageal samples from 86 patients representing the Ba

249 Comparison of oesophageal sampling methods showed that the Cytosponge

250 A tissue-engineered oesophageal scaffold could be very useful for the treatm

251 We consider the presented tissue-engineered oesophageal scaffolds a significant step towards the cli

252 ngth 120 mm) to bridge a 5 cm full-thickness oesophageal segment destroyed by a mediastinal abscess a

253 assembly was drawn through the human gastro-oesophageal segment to correlate sphincteric pressure wi

254 ined neural responses to phasic, non-painful oesophageal sensation (OS) in eight healthy subjects (se

255 regut lengthening despite failure of tracheo-oesophageal separation in Adriamycin-treated embryos, wh

256 ssion is proposed to be critical for tracheo-oesophageal separation.

257 Lower oesophageal sphincter (LES) pressure was higher in patie

258 ux, that is, gastric distension-evoked lower oesophageal sphincter (LOS) relaxation.

259 ux, that is, gastric distension-evoked lower oesophageal sphincter (LOS) relaxation.

260 cadavers have led some to identify the lower oesophageal sphincter (LOS) with the anatomical gastric

261 itric oxide concentrations both at the lower oesophageal sphincter and within the vasculature may be

262 ute to laryngeal vestibule closure and upper oesophageal sphincter opening during swallowing.

263 stalsis and impaired relaxation of the lower oesophageal sphincter.

264 e inhibitors have efficacy in EGFR-amplified oesophageal squamous cell carcinoma (ESCC), but may beco

265 anol-derived definite carcinogen that causes oesophageal squamous cell carcinoma (ESCC).

266 Oesophageal squamous cell carcinoma is a deadly disease

267 gnostic factor in patients with unresectable oesophageal squamous cell carcinoma.

268 Subjects included 498 oesophageal squamous cell carcinomas (OSCCs), 255 gastri

269 aracterised by replacement of reflux-damaged oesophageal squamous epithelium with a columnar intestin

270 Ulceration of the oesophageal squamous mucosa (ulcerative oesophagitis) is

271 As that are differentially expressed between oesophageal squamous mucosa and Barrett's oesophagus muc

272 location and function of these microRNAs in oesophageal squamous mucosa from individuals with ulcera

273 R-145 and miR-205 expression was observed in oesophageal squamous mucosa of individuals with ulcerati

274 ed definitive CRT in patients with localised oesophageal squamous-cell cancer and adenocarcinomas to

275 pproximately half of the world's 500,000 new oesophageal squamous-cell carcinoma (ESCC) cases each ye

276 ediate autonomic responses evoked by noxious oesophageal stimuli and participate in the perception of

277 ential for mouth opening during feeding, and oesophageal striated muscle (OSM), which is crucial for

278 Pharyngo-oesophageal stricture (PES) is a serious complication th

279 The most frequent complications of oesophageal surgery are respiratory and these are associ

280 al nature of respiratory complications after oesophageal surgery may mean that a number of interventi

281 If unrecognized and injured during oesophageal surgery, it can lead to disastrous complicat

282 velopment of respiratory complications after oesophageal surgery.

283 n established between volume and outcome for oesophageal surgery.

284 er improve the safety of patients undergoing oesophageal surgery.

285 taking HRT rely on self-reporting of gastro-oesophageal symptoms and the aetiology of gastro-oesopha

286 ients who were referred for investigation of oesophageal symptoms were recruited at Nottingham Univer

287 establish motility disorders as the cause of oesophageal symptoms.

288 PFO+ subjects had a higher oesophageal temperature (T(oesoph)) (P < 0.05) than PFO-

289 Their levels in oesophageal tissue, however, do not distinguish patients

290 comitant with higher serum IgE levels and an oesophageal transcriptome indicative of a more-pronounce

291 e surgeon to safely operate on patients with oesophageal tumours and to tailor the procedure on the b

292 d in the treatment of premalignant and early oesophageal tumours.

293 s with advanced breast and gastric or gastro-oesophageal tumours.

294 the 86 patients who underwent endoscopy was oesophageal varices (57%), followed by peptic ulcer dise

295 ollapse [possibly related to sunitinib], one oesophageal varices haemorrhage [possibly related to sun

296 tinib group (one case each of renal failure, oesophageal varices haemorrhage, circulatory collapse, w

297 readmission due to UGIB in 4 patients (2.4%) Oesophageal varices was the most common cause of UGIB.

298 Oesophageal varices were the commonest finding in patien

299 Atropine resulted in an increase in the oesophageal wall compliance during isobaric distension,

300 The oesophageal wall compliance, circumferential wall tensio